Wall Street analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to announce earnings per share (EPS) of ($0.27) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Amicus Therapeutics’ earnings, with estimates ranging from ($0.29) to ($0.25). Amicus Therapeutics posted earnings of ($0.41) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 34.1%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Amicus Therapeutics will report full year earnings of ($1.18) per share for the current year, with EPS estimates ranging from ($1.23) to ($1.11). For the next fiscal year, analysts expect that the company will post earnings of ($0.75) per share, with EPS estimates ranging from ($1.20) to ($0.29). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.33). Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. The firm had revenue of $21.31 million for the quarter, compared to analysts’ expectations of $18.92 million.

Several equities research analysts have commented on FOLD shares. Cowen restated a “buy” rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research note on Tuesday, May 8th. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, May 4th. ValuEngine lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 19th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Tuesday, July 10th. Finally, Chardan Capital lowered shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $18.00 to $15.00 in a research note on Friday, August 17th. One analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $19.43.

In other Amicus Therapeutics news, SVP Kurt J. Andrews sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $15.63, for a total value of $78,150.00. Following the sale, the senior vice president now owns 40,469 shares in the company, valued at $632,530.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William D. Baird III sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $15.63, for a total transaction of $156,300.00. Following the completion of the sale, the chief financial officer now owns 117,622 shares in the company, valued at approximately $1,838,431.86. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in FOLD. Rhumbline Advisers increased its stake in shares of Amicus Therapeutics by 9.7% during the first quarter. Rhumbline Advisers now owns 173,506 shares of the biopharmaceutical company’s stock valued at $2,610,000 after acquiring an additional 15,275 shares during the period. Mackay Shields LLC acquired a new position in shares of Amicus Therapeutics during the first quarter valued at approximately $993,000. American Century Companies Inc. increased its stake in shares of Amicus Therapeutics by 138.9% during the first quarter. American Century Companies Inc. now owns 239,386 shares of the biopharmaceutical company’s stock valued at $3,600,000 after acquiring an additional 139,179 shares during the period. Victory Capital Management Inc. increased its stake in shares of Amicus Therapeutics by 15.5% during the first quarter. Victory Capital Management Inc. now owns 3,055,299 shares of the biopharmaceutical company’s stock valued at $45,951,000 after acquiring an additional 410,375 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its stake in shares of Amicus Therapeutics by 11.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 765,421 shares of the biopharmaceutical company’s stock valued at $11,512,000 after acquiring an additional 80,306 shares during the period.

Shares of NASDAQ FOLD opened at $13.61 on Tuesday. The company has a quick ratio of 10.73, a current ratio of 10.88 and a debt-to-equity ratio of 0.30. Amicus Therapeutics has a 52-week low of $12.20 and a 52-week high of $17.62.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Featured Article: Stock Symbol

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.